Results 51 to 60 of about 4,101 (234)

Demyelinating Polyradiculoneuropathy in Chronic Lymphocytic Leukemia: A Case Report on BTKis versus Venetoclax-Rituximab

Hemato, 2023
The dysregulation of the immune system in Chronic Lymphocytic Leukemia (CLL) often allows for the development of immune-mediated diseases. Among them, autoimmune cytopenias are the most common, but cases of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) have been reported.
Alessandro Cellini, Andrea Visentin, Alessandro Salvalaggio, Mario Cacciavillani, Sergio Ferrari, Chiara Briani   +5 more
openaire   +4 more sources

Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials

Molecules, 2023
In the last few decades, there has been a growing interest in Bruton’s tyrosine kinase (BTK) and the compounds that target it. BTK is a downstream mediator of the B-cell receptor (BCR) signaling pathway and affects B-cell proliferation and differentiation.
Dariusz Rozkiewicz, Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, Anna Krupa, Dariusz Pawlak   +4 more
openaire   +3 more sources

Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy [PDF]

The Journal of Pathology
AbstractIn recent years, targeted therapies have become the standard of care for refractory/relapsed mantle cell lymphoma (MCL). Although the mutational profile of MCL has been extensively studied, there is a lack of understanding of resistance mechanisms and genetic factors that impact the response to novel treatments.
Tamás László, László Imre Pinczés, Bence Bátai, Luca Varga, Botond Tímár, Anita Gulyás, Ilona Tárkányi, Márk Plander, Zsolt Nagy, Péter Rajnics, Miklós Egyed, Zsuzsa Molnár, János Rottek, András Masszi, Péter Tamáska, Róbert Szász, Árpád Illés, Donát Alpár, Ferenc Magyari, Csaba Bödör   +19 more
openalex   +3 more sources

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial

Haematologica
Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment of B-cell malignancies, but intolerance has often led to their discontinuation. The phase 1/2 BRUIN study evaluated pirtobrutinib, a highly selective non-covalent (reversible) BTKi,
Nirav N. Shah, Michael Wang, Lindsey E. Roeker, Krish Patel, Jennifer A. Woyach, William G. Wierda, Chaitra S. Ujjani, Toby A. Eyre, Pier Luigi Z inzani, Alvaro J. Alencar, Paolo Ghia, Nicole Lamanna, Marc S. Hoffmann, Manish R. Patel, Ian Flinn, James N. Gerson, Shuo Ma, Catherine C. Coombs, Chan Y. Cheah, Ewa Lech-Maranda, Bita Fakhri, Won Seog Kim, Minal A. Barve, Jonathon B. Cohen, Wojciech Jurczak, Talha Munir, Meghan C. Thompson, Donald E. Tsai, Katherine Bao, Nicholas A. Cangemi, Jennifer F. Kherani, Richard A. Walgren, Hongmei Han, Amy S. Ruppert, Jennifer R. Brown   +34 more
doaj   +1 more source

Bruton’s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review

Frontiers in Oncology, 2022
Primary central nervous system lymphoma (PCNSL) is a highly aggressive brain tumor with poor prognosis if no treatment. The activation of the NF-κB (nuclear factor kappa-B) is the oncogenic hallmark of PCNSL, and it was driven by B cell receptor (BCR ...
Jing Shen, Jinghua Liu, Jinghua Liu
doaj   +1 more source

Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option [PDF]

, 2023
Ibrutinib, the first-in-class Bruton’s tyrosine kinase inhibitor (BTKi), is a commonly deployed therapeutic option for previously untreated and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia (CLL).
Allsup, David, Molica, Stefano, Polliack, Aaron, Tam, Constantine   +3 more
core   +1 more source

Efficacy and safety of first- versus second-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis

Frontiers in Pharmacology
We conducted this first systematic review and meta-analysis to assess the competitive advantage of 2nd-generation Bruton tyrosine kinase inhibitors (BTKi) compared to 1st-generation BTKi in chronic lymphocytic leukemia (CLL).
Liyuan Ke, Su Li, Danxue Huang, Yan Wang
doaj   +1 more source

Manfaat Korelasi Sni-hs 2013 Dalam Rangka Mendukung Pengembangan Dan Penerapan Sni [PDF]

, 2014
Pertumbuhan jumlah SNI yang cepat dengan rata-rata 370 SNI per tahun terjadi dalam dua tahun terakhir. Kodefikasi Harmonize System (HS) di Indonesia sesuai Buku Tarif Kepabeanan Indonesia (BTKI) dilakukan revisi per 5 tahun.
Purwanto, E. H. (Endi), Tampubolon, B. D. (Biatna)   +1 more
core  

Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single‐Cell Multi‐Omics

American Journal of Hematology, EarlyView.
ABSTRACT Pirtobrutinib (PBN), a non‐covalent BTK inhibitor, has been approved by the FDA for relapsed/refractory mantle cell lymphoma (MCL); however, resistance to PBN has been observed. To dissect the molecular dynamics driving PBN resistance, we performed integrative single‐cell multi‐omic profiling (scRNA‐seq, scATAC‐seq, and scDNA‐seq) on ...
Fangfang Yan, Yang Liu, Heng‐Huan Lee, Wei Wang, Joseph McIntosh, Yijing Li, Jovanny Vargas, Yue Fei, Sairah Ahmed, Lukas M. Simon, Michael Wang   +10 more
wiley   +1 more source

UA12/2/1 College Heights Herald, Vol. 51, No. 17 [PDF]

, 1975
WKU campus newspaper reporting campus, athletic and Bowling Green, Kentucky news. This issue contains articles: Adams, Anne & Jay Wethington. Off-Campus Housing: Make a Choice, Take a Chance 17 Candidates Seek Homecoming Crown Harris, Roger.
WKU Student Affairs
core   +3 more sources